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Abstract 
Background:  There are conflicting reports regarding the prognosis of heart failure patients 
with preserved (HFPSF) comparative to reduced systolic left ventricular function (HFRSF). 
We evaluated the clinical characteristics, mortality rates and modes of death in 309 
consecutive symptomatic heart failure patients. In 133(56%) patients LVEF was <50% 
(HFRSF), and in 133 (44%), LVEF was ≥50% (HFPSF). 
Methods: Three hundred nine consecutive patients hospitalized between January 1, 2009 and 
January 1, 2010 (176 men and 133 women, mean age 64.3 years) were followed up for a 
mean period of 23±14 months. The severity of symptoms at admission was assessed by 
NYHA classification. 196 patients were in NYHA class I-II, and 113 in III–IV. All patients 
underwent chest X-ray, echocardiogram, and a 6-minute walking test.  We compared the 
clinical profiles, mortality rates and modes of death.  
Results: More than a third (44%) of the patients had preserved systolic LVEF based on 
echocardiography. Compared to the HFPSF group, HFRSF patients were predominantly 
younger males with ischemic aetiology and less cardiovascular comorbidities such as obesity, 
hypertension, diabetes mellitus and atrial fibrillation. During a mean follow-up period of 1.9
years, 22 (7.1%) patients died: 14 of cardiac causes and 8 of non-cardiac causes (4 of 
respiratory causes, 2 of stroke, 1 of major bleeding and 1 of cancer).  Overall mortality was 
similar between the two groups:   8 (6%) in HFPSF patients and 14 (7.9%) in HFRSF patients 
(p=0.67). HFRSF patients had  higher death rates due to pump failure compared to the HFPSF 
group [ 5/14(36%) vs. 1/8(12%) patients, p=0.5]. Non-cardiac deaths were more frequent in 
HFPSF group [4/8 (50%) patients vs. 4/14(28%) patients, respectively, p=0.5]. The 
prevalence of arrhythmic death was similar in the two groups [5/14(36%) vs.3/8(37%) 
patients, p=0.6]. With Cox stepwise regression analysis for survival, the independent 
predictors for mortality were age, gender, ischemic etiology of heart failure and renal 
impairment.   
Conclusions: Although the characteristics of HFPSF and SHF patients are different, the 
mortality rates were similar in our study. The mode of death was different among the two 
groups of patients, as pump failure death rate was higher in patients with LVEF <50%, while  
non-cardiac death was higher in heart failure patients with preserved systolic function. The 
differences were not statistically significant. A high NYHA class at admission, age over 65, 
male gender and renal impairment were related to a worse prognosis. 
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Background 
 Heart failure (HF) represents a significant health problem /1/. Heart failure with 
preserved systolic left ventricular function (HFPSVF) is a common condition in heart failure 
patients and represents as a serious clinical problem. The literature indicates that over the last 
years the number of patients hospitalized with heart failure and preserved LVF is increasing 
/2/. The prognosis in these patients was considered to be better than in patients with low LVF. 
However, some studies suggest that the outcome in these patients is not so good /3/. 
Regarding these conflicting data, we aimed to evaluate the mortality and morbidity in patients 
with heart failure and preserved LVF compared to those in patients with reduced LVF.  
 
Methods  
 Our HF centre is a secondary teaching centre, assembling most HF patients in the 
south-west counties of Romania. We included in the study HF patients who were hospitalized 
in our department for symptomatic HF. We reviewed patients' records for clinical, laboratory, 
echocardiographic and electrocardiographic parameters. 309 consecutive patients hospitalized 
between January 1, 2009 and January 1, 2010 (176 men and 133 women, mean age 64.3 
years). The patients were followed up for a mean period of 23±14 months. The severity of 
symptoms at admission was assessed by NYHA classification. 65 (21%) patients were in 
NYHA class I, 131 (42%) in II, and 113 (37%) in III–IV. All patients underwent chest X-ray, 
echocardiogram, and a 6-minute walking test.  We compared the clinical profiles, mortality 
rates and modes of death.  We categorized HFPSF as symptomatic HF patients with left 
ventricular ejection fraction (LVEF) ≥ 50% and HFRSF as symptomatic HF patients with 
LVEF < 50% per echocardiogram. We analyzed in- hospital mortality rates.  22 patients (7%) 
died during the follow-up period. The mode of death was categorized as hemodynamic 
cardiac death (pump failure), arrhythmic (sudden) cardiac death or non-cardiac. 
Hemodynamic cardiac death mode was defined as worsening heart failure (cardiogenic shock, 
pulmonary edema or increase in heart failure symptoms and drug therapy) prior to death. 
Arrhythmic death mode was defined as instantaneous or acute in clinical setting (within 24 h), 
in the absence of pre-existing circulatory failure.  A non-cardiac death included a variety of 
etiologies of mortality (stroke, respiratory infection, cancer, major bleeding).  
 
Data analysis  
 Continuous data are presented as numbers or means ± standard deviation, and 
categorical variables as numbers and percentages. The independent samples t-test was used to 
compare continuous variables, and the chi-square test was used to compare categorical 
variables. Fisher's exact test was used in cases of small sample sizes. Survival curves were 
plotted by the Kaplan–Meier method, using the log-rank test for comparison between the two 
ejection fraction groups. In order to determine the adjusted hazard ratio for death among 
patients with HFRHF and HFPSF, we used Cox proportional-hazards multivariate analysis. 
The results were considered statistically significant when the p-value was <0.05. The 
MedCalc 12.3.0.0 statistical software for Windows was used to perform statistical analysis. 
Parameters included in the multivariate stepwise Cox regression analysis included all 
significant clinical and laboratory parameters, as well as drug treatment, on univariate 
analysis. Parameters  included in the multivariate analysis were gender, age, body mass index, 
NYHA class at admission, ischemic heart disease, hypertension, diabetes, atrial fibrillation, 
serum urea, glomerular filtration rate (GFR) for serum creatinine (derived from the MDRD 
Study equation), NT-proBNP, sodium, hemoglobin, distance at 6-min walk test, ED-5D-5L 
quality of life score /3/, Hamilton depression score /4/ and LVEF. 
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Results  
 The study analysis included 309 patients who were followed at our HF centre for a 
mean period of 23±14 months. This cohort of patients included 176 (56%) patients with 
HFRSF and 133 (44%) patients with HFPSF. Patients' mean age was 64.3 years, 133 (43%) 
patients were females. Patients' characteristics according to their HF profile (HFRSF/HFPSF) 
are presented elaborated in table 1. Their baseline laboratory data are detailed in table 2. 
Table 1. Characteristics of HFRSF and HFPSF patients. 
Variable EF<50% (n=176) EF≥50% (n=133) p-value 
Age (years) 66 ±7.5 
 
61± 8.9 <0.0001 
Female gender 60 (34%) 73 (55%) 0.0003 
Body mass index (kg/m2) 31± 6.2 33±2.5 0.0005 
Ischemic etiology  
n (%) 
110 (63%) 46 (35%) <0.03 
History of hypertension n 
(%) 
93 (53%) 101 (76%) 0.0001 
Diabetes mellitus n (%) 51 (29%) 65 (48%) 0.001 
Atrial fibrillation n (%) 56 (32%) 66 (50%) 0.002 
Six-minute walk (m) 181± 38 261±64 <0.0001 
New York Heart 
Association Class  
(1–4)  
2.5 ± 0.4 2.1 ± 0.8 < 0.0001 
EQ-5D-5L Euro QOL 
score/4/ 
50± 15 31.2±12.7 < 0.0001 
Hamilton Depression Scale 
score/5/ 
8.7±3.1 7.2±2.8 < 0.0001 
Beta blockers therapy  
n (%) 
151 (86%) 110 (84%) NS 
ACEI/ARBb therapy  
n (%) 
110 (63%) 87 (66%) NS 
Spironolactone therapy n 
(%) 
142 (81%) 47 (36%) <0.0001 
Diuretics therapy n (%) 163 (93%) 119 (90%) NS 
    
Continuous variables are presented as mean ± 1 standard deviation  
EF= ejection fraction; ACEI=angiotensin-converting enzyme inhibitors; ARB=angiotensin receptor blockers. 
EQ-5D-5L: measurement of health-related quality of life scale, EuroQOL Group.  
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Table 2. Laboratory tests of HFRSF and HFPSF patients. 
Variable EF<50% (n=176) EF≥50% (n=133) p-value 
Hemoglobin (g/dl) 13.8±1.7 14.5±1.8 0.0005 
Ht (%) 43.4±5.1 43.6±4.3 NS 
Creatinine (mg/dl) 1.18±0.29 0.99±0.28 <0.0001 
Urea (mg/dl) 30±19.8 24±11.5 0.002 
GFR (ml/min/1.73 m2) 57.58±19 74.28±19 <0.0001 
Sodium (mEq/l) 136.5 ± 3.2 137.4 ± 3.4 0.01 
Uric acid (mg/dl) 6.0±1.6 7.0±3.3 0.0005  74.28±19 <0.0001 
Total cholesterol 
(mg/dl) 
157.0  ± 34 163.0 ± 42 NS 
NT-proBNP (pg/ml) 821.4±720 520.8±360 < 0.0001 
Data are presented as mean± 1 standard deviation  
  
As we see, the clinical profile of the HFPSF patient is different from the HFRSF 
patient. HFPSF patients are more likely to be younger, have female gender and a higher 
prevalence of cardiovascular comorbidities, such as obesity, diabetes mellitus, hypertension, 
renal impairment and atrial fibrillation. Patients with HFRSF are more frequently older men, 
with ischemic heart disease; they have a higher NYHA class, a higher depression scale score, 
a lower distance at six-minute walk test, a poorer quality of life and higher levels of NT-
proBNP. The treatment in both heart failure group patients was similar, excepting a higher 
rate of Spironolactone receiving patients among those having  LVEF< 50% (p<0.0001).  
 
Fig.1. Kaplan–Meier survival curves in HFRSF and HFPSF patients (p-value 0.9, Log-rank test). 
 
 During mean follow-up period of 23±14 months, 22 (7%) patients died. The mortality 
rates of both SHF and the HFPSF patients groups were similar: 14 (7.9%) in HFRSF and 8 
(6%) in HFPSF; p=0.67. At log-rank test for Kaplan-Meyer survival curves: p=0.9 (fig.1). 
 We analyzed the possible association of the following parameters with mortality: LVEF, age, 
gender, atrial fibrillation, diabetes mellitus, hypertension, ischemic etiology and body mass 
index (table 3).  Using Cox stepwise multivariate analysis, we found that age, gender, 
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ischemic etiology of heart failure and increased serum urea were independent variables 
associated with mortality. 
Table 3. Cox logistic regression multivariate analysis for mortality. 
Variable HR (95% CI)a p-value 
Age 1.04 (1.00–1.08) 0.02 
Gender 1.05 (1.05–2.45) 0.006 
Ischemic heart disease 1.50 (1.05–2.63) 0.005 
Urea 1.03 (1.01–1.06) 0.02 
NYHA class 1.42 (1.04– 2.18) 0.03 
 
As demonstrated in fig.3, the HFRSF patients had a  higher prevalence of mortality 
due to pump failure comparing with the HFPSF patients, but the difference was not 
statistically significant [5/14 (36%) patients vs. 1/8 (13%), p=0.5]. The prevalence of sudden 
cardiac death was similar [5/14 (36%) vs. 3/8 (37%), p=0.6]. Non-cardiac deaths were more 
frequent in heart failure patients with preserved systolic function [ 4/8 (50%) vs. 4/14 (28%), 
p=0.6](fig.3).  
 
 
Discussion  
 The main finding of this study is that, although there are large differences in the 
clinical profiles of heart failure patients with reduced or preserved systolic function, mortality 
is similar.   
 However, we observe that the prevalence of various modes of death is different. In 
patients with reduced systolic function, death rate due to aggravated heart failure was 2.7 
times more common than in patients with preserved systolic function, while non-cardiac death 
rate was 1.7 times more common in HFPSF.  Arrhythmic (sudden) cardiac death rate was 
similar in both groups.  
 There are many controversies regarding HFPSF. In definition, cut-off value of normal 
LVEF varies between 35% and 50%.  Although many studies and guidelines for diagnosing 
heart failure with preserved systolic function were published in the last years, there is no 
consent regarding the definition.  We chose as cut-off value for HF with preserved systolic 
function a   LVEF ≥ 50% /8/. 
 Probably due to definition variations, the  prevalence of HFPSF is controversial, 
between 24% and 60% of the total HF population, usually higher in older HF patients /9,10/. 
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In our study, HFPSF patients were younger, were more frequent females and had a higher 
prevalence of cardiovascular comorbidities, such as obesity, diabetes mellitus, hypertension, 
renal impairment and atrial fibrillation. Similar results were observed in other studies/11, 12/. 
In contrast, heart failure patients with reduced LVEF were more frequent males and older. 
Reduced systolic function heart failure was associated more frequent with ischemic etiology, 
higher levels of NT-proBNP, depression and a poorer quality of life. /13, 14, 15, 16, 17/ Heart 
failure treatment with beta-blockers, ACE inhibitors, angiotensin receptor antagonists and 
diuretics was similar in both groups. Spironolactone had a significant statistical higher usage 
in patients with reduced LVEF, probably due to more severe signs and symptoms of heart 
failure.   /18, 20/.  
 The mortality rate in our study was 7.1% (7, 9% in HFRSF and 6% in HFPSF patients, 
p=0.67). 0ver the follow-up period of 23±14  months, the total mortality rate was similar in 
the two groups. The mechanisms of death were different, but no statistically significant. In 
patients with LVEF < 50%, the major cause of death was the aggravation of heart failure. 
Among patients with preserved systolic function, non-cardiac causes of death (stroke, cancer, 
major bleeding) were predominant . Sudden cardiac deaths had similar rates in the two study 
groups.  
 Our data are concordant to those reported, as several studies demonstrate similar 
mortality rates among  heart failure patients with reduced and preserved systolic function 
/8,19,22,23,24/.  
 As regarding medical treatment, excepting Spironolactone, that was used more 
frequent in patients with LVEF< 50%, there were not significant differences among the two 
groups. The beneficial effect of aldosterone receptor antagonism was demonstrated in systolic 
heart failure (Ephesus study/20/), while its effect in preserved LV heart failure is now being 
tested (Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone 
Antagonist -TOPCAT study)/21/. 
 The similar rate of arrhythmic (sudden) cardiac death in the two patient groups leads 
to the question of a potential benefit of implantable cardioverter-defibrillator devices in 
patients with heart failure having a preserved systolic function /24/. 
 
Conclusions 
 The arbitrary cut-off levels of LVEF in different HFPSF studies lead to controversies 
regarding the patient cohort. 
 The prognosis of heart failure patients is poor, indifferent of the LVEF. 
 Heart failure patients with reduced and preserved systolic function have different 
clinical characteristics, but similar total mortality rates. Death due to pump failure is higher 
among patients with reduced LVEF, while non-cardiac death occurs at higher rates in those 
with preserved LV systolic function.  
 As arrhythmic cardiac death has similar rates in both types of heart failure, more 
efforts have to be done to prevent it.  
 The treatment protocol of HF with preserved LVEF has to be improved. 
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